{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2025-09-19", "results": { "skip": 0, "limit": 1, "total": 1 } }, "results": [ { "codes": [ { "uuid": "1c2d89de-482c-4ba9-879d-c2ab2f588590", "code": "P14416", "type": "PRIMARY", "url": "http://www.uniprot.org/uniprot/P14416?sort=score", "code_system": "UNIPROT", "references": [ "6be1949a-09b7-455f-9eae-38cf6412c9d4" ] }, { "uuid": "65f5e04d-b1a5-4b49-b8f7-05ff9f313dda", "code": "P14416", "type": "PRIMARY", "url": "https://pharos.nih.gov/idg/search?q=P14416", "code_system": "PHAROS", "references": [ "6be1949a-09b7-455f-9eae-38cf6412c9d4" ] }, { "uuid": "d292543b-955d-4e1d-b1a1-e318c0123e3c", "code": "19GBD6T9L7", "type": "PRIMARY", "code_system": "FDA UNII" } ], "substance_class": "protein", "references": [ { "uuid": "77f40706-07bb-4631-8487-897b4cdecf5a", "citation": "https://pubchem.ncbi.nlm.nih.gov/compound/Metopimazine#section=Biological-Test-Results", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Metopimazine", "doc_type": "PUBCHEM", "public_domain": true, "tags": [ "POT" ] }, { "uuid": "d72181ea-2e46-4f2e-8197-cf4279ff6ca4", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "7fdc675a-9238-494a-8877-6cfa08878db2", "citation": "http://www.uniprot.org/uniprot/P14416", "url": "http://www.uniprot.org/uniprot/P14416", "doc_type": "SRS", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE", "AUTO_SELECTED" ] }, { "uuid": "fa5ad85a-51a9-4a93-ac80-9966529aa0c3", "citation": "UNIPROT", "doc_type": "UNIPROT", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "3741bcc3-f436-403d-80a0-3b34b77149e3", "citation": "http://www.uniprot.org/uniprot/P14416?sort=score", "url": "http://www.uniprot.org/uniprot/P14416?sort=score", "doc_type": "UNIPROT", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "6be1949a-09b7-455f-9eae-38cf6412c9d4", "citation": "SRS CODE IMPORT", "doc_type": "SRS", "public_domain": true, "document_date": 1493393475000, "tags": [ "NOMEN" ] }, { "uuid": "1c1864cd-bd16-4fdd-8961-6823e07db9d5", "citation": "SRS import [19GBD6T9L7]", "url": "http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=19GBD6T9L7", "doc_type": "SRS", "public_domain": true, "document_date": 1493393475000, "tags": [ "NOMEN" ] }, { "uuid": "653f9470-fd4f-4331-92bb-da840f932a81", "citation": "eurofinsdiscovery", "url": "https://www.eurofinsdiscoveryservices.com/catalogmanagement/viewItem/1405", "doc_type": "WEB PAGE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "95cbea44-2697-423d-91c1-95c526cbdbf0", "citation": "https://www.prnewswire.com/news-releases/renexxion-ireland-announces-issuance-of-a-new-us-patent-covering-naronapride-a-clinical-stage-potential-best-in-class-prokinetic-agent-for-gastrointestinal-disorders-301450410.html", "url": "https://www.prnewswire.com/news-releases/renexxion-ireland-announces-issuance-of-a-new-us-patent-covering-naronapride-a-clinical-stage-potential-best-in-class-prokinetic-agent-for-gastrointestinal-disorders-301450410.html", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "3d4010db-c709-445a-8410-7b19cb7b6048", "citation": "eurofinsdiscovery", "url": "https://www.eurofinsdiscoveryservices.com/catalogmanagement/viewItem/1405", "doc_type": "WEB PAGE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "5929a3e2-5efd-4b69-a4cd-d02328ba965f", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "3718e16b-20de-40c4-9112-a8ac3abe0945", "citation": "https://en.wikipedia.org/wiki/Raclopride", "url": "https://en.wikipedia.org/wiki/Raclopride", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "cda44665-bfdb-4bd3-b556-7fb067960681", "citation": "https://drugs.ncats.io/drug/D7UUO54C6N", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "4421af0d-a03b-4391-8a6e-0b4ec1e9fe9f", "citation": "Chiò, Adriano, Letizia Mazzini, and Gabriele Mora. \"Disease-modifying therapies in amyotrophic lateral sclerosis.\" Neuropharmacology 167 (2020): 107986.", "url": "https://www.sciencedirect.com/science/article/pii/S0028390820300526", "doc_type": "JA", "public_domain": true }, { "uuid": "5cdb941a-b124-4af6-8b9e-c651bc57b5a4", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf", "doc_type": "NDA PUBLIC REVIEW", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c944595d-8190-48ad-9f12-816229dfa66d", "citation": "https://www.drugbank.ca/drugs/DB06216", "doc_type": "WEBSITE", "public_domain": true }, { "uuid": "5718337b-370e-4692-84be-40889810b6d6", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022117s000lbl.pdf", "doc_type": "NDA PUBLIC REVIEW", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "e424bfdb-fb12-40ce-b9ac-05c8be9ea918", "citation": "https://www.drugbank.ca/drugs/DB00714#BE0000581", "doc_type": "WEBSITE", "public_domain": true }, { "uuid": "68c9cfda-b324-4fde-87a4-026cc9c059b8", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-264_Apokyn_Pharmr_P2.pdf", "doc_type": "NDA PUBLIC REVIEW", "public_domain": true }, { "uuid": "8f98ee6c-257c-45f6-b3d8-be3b37d235fa", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf", "doc_type": "NDA PUBLIC REVIEW", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "466c79ca-c7e7-4d8f-8f4b-26b7cc85f47c", "citation": "P122", "doc_type": "INN", "public_domain": true }, { "uuid": "560fe97a-3150-4a93-8110-f2c5dcc910e5", "citation": "Megens, A. A., et al. \"Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).\" Journal of Pharmacology and Experimental Therapeutics 260.1 (1992): 146-159.", "url": "http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.834.7852&rep=rep1&type=pdf", "doc_type": "JA", "public_domain": true }, { "uuid": "3f785666-a165-4d54-880c-b7743a49c2a4", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf", "doc_type": "NDA PUBLIC REVIEW", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "5de97546-2c14-4f0e-a53b-6683e713a815", "citation": "P122", "doc_type": "INN", "public_domain": true }, { "uuid": "712489ee-d8ee-40e5-8b57-6d4c842b19f5", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf", "doc_type": "FDA APPROVED DRUG LABEL", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "f9aa99c5-50db-11c8-f648-9d4f71589099", "citation": "Pan, Xiongfeng, et al. \"Dopamine and dopamine receptors in Alzheimer’s disease: a systematic review and network meta-analysis.\" Frontiers in aging neuroscience 11 (2019): 175.", "url": "https://www.frontiersin.org/articles/10.3389/fnagi.2019.00175/full", "doc_type": "JA", "public_domain": true }, { "uuid": "677df83d-6017-4231-a9bb-5db2edfce886", "citation": "Corena-McLeod, Maria. \"Comparative pharmacology of risperidone and paliperidone.\" Drugs in R&D 15.2 (2015): 163-174.", "url": "https://link.springer.com/article/10.1007/s40268-015-0092-x", "doc_type": "JA", "public_domain": true }, { "uuid": "e811f88e-3b72-4077-90ac-2b2bd2adf43f", "citation": "Corena-McLeod, Maria. \"Comparative pharmacology of risperidone and paliperidone.\" Drugs in R&D 15.2 (2015): 163-174.", "url": "https://link.springer.com/article/10.1007/s40268-015-0092-x", "doc_type": "JA", "public_domain": true }, { "uuid": "20c58ea2-ef23-487b-b4d9-eaac57742577", "citation": "Prakash, Chandra, et al. \"Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers.\" Drug metabolism and disposition 26.5 (1998): 448-456.", "url": "https://dmd.aspetjournals.org/content/dmd/26/5/448.full.pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "702f6fa8-d005-458a-94e7-bacf1cfb7e49", "citation": "Jaquet, P., et al. \"BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.\" Journal of endocrinological investigation 28.11 Suppl International (2005): 21.", "url": "https://www.ncbi.nlm.nih.gov/pubmed/16625841", "doc_type": "JA", "public_domain": true, "tags": [ "POT" ] }, { "uuid": "99563024-e0ea-4f6b-bb5b-30745f4dbc87", "citation": "Corena-McLeod, Maria. \"Comparative pharmacology of risperidone and paliperidone.\" Drugs in R&D 15.2 (2015): 163-174.", "url": "https://link.springer.com/article/10.1007/s40268-015-0092-x", "doc_type": "JA", "public_domain": true }, { "uuid": "520a3fd6-bbde-42f6-8eab-8ef207eb17cb", "citation": "Feng, Meihua Rose, Joseph Loo, and Jonathan Wright. \"Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome p450 2D6 extensive metabolizers: Species comparison and allometric scaling.\" Drug metabolism and disposition 26.10 (1998): 982-988.", "url": "https://dmd.aspetjournals.org/content/dmd/26/10/982.full.pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "632b99ff-2586-404d-8408-dbdb0abda2e4", "citation": "Domperidone deuterated - CinRx Pharma", "url": "https://adisinsight.springer.com/drugs/800050807", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "673cdba1-9e14-429b-8cdd-031225700e10", "citation": "Jaquet, P., et al. \"BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.\" Journal of endocrinological investigation 28.11 Suppl International (2005): 21.", "url": "https://www.ncbi.nlm.nih.gov/pubmed/16625841", "doc_type": "JA", "public_domain": true, "tags": [ "POT" ] }, { "uuid": "3d2995a8-6ba9-4be6-b206-83462fd138d5", "citation": "Mesens, Natalie, et al. \"Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.\" Toxicology in vitro 24.5 (2010): 1417-1425.", "url": "https://www.sciencedirect.com/science/article/pii/S0887233310000901", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "048a98f5-69a1-4f12-9974-9ba71391f812", "citation": "https://en.wikipedia.org/wiki/Dopamine_receptor_D2", "url": "https://en.wikipedia.org/wiki/Salvinorin_A", "doc_type": "JA", "public_domain": true }, { "uuid": "9d619464-9897-4cb1-a1e0-346b41b98c65", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "bc49d4dd-269b-4691-a49b-4c328bb29b94", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "58d5b633-d571-428d-91e1-35ba05cc644b", "citation": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000PharmR.pdf", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000PharmR.pdf", "doc_type": "NDA PUBLIC REVIEW", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8d23b4ac-48ff-472b-83bc-d0cffb719db2", "citation": "Kaur, Sunpreet, et al. \"Pharmacology of Dopamine and Its Receptors.\" Frontiers in Pharmacology of Neurotransmitters. Springer, Singapore, 2020. 143-182.", "url": "https://www.researchgate.net/profile/Gagandeep-Jaiswal-2/publication/346034610_Pharmacology_of_Dopamine_and_Its_Receptors_Frontiers_in_Pharmacology_of_Neurotransmitters_pp_143-182_Cite_as/links/5ff0151c299bf1408864c3f1/Pharmacology-of-Dopamine-and-Its-Receptors-Frontiers-in-Pharmacology-of-Neurotransmitters-pp-143-182-Cite-as.pdf", "doc_type": "JA", "public_domain": true }, { "uuid": "14ffbaf1-253a-458b-ac5a-b09bfc63631e", "citation": "WEBSITE", "url": "https://comptox.epa.gov/dashboard/dsstoxdb/results?utf8=%E2%9C%93&search=749-02-0", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "11681e73-4785-4b2c-a5c3-ac50824e5aa0", "citation": "Palacios, J. M., D. L. Niehoff, and M. J. Kuhar. \"[3H] Spiperone binding sites in brain: autoradiographic localization of multiple receptors.\" Brain research 213.2 (1981): 277-289.", "url": "https://link.springer.com/content/pdf/10.1007/BF01250639.pdf", "doc_type": "JA", "public_domain": true }, { "uuid": "38ba70f9-5336-4c97-9841-c833e6a9e1fa", "citation": "SRS import [4X6E73CJ0Q]", "url": "http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=4X6E73CJ0Q", "doc_type": "SRS", "public_domain": true, "document_date": 1493390165000, "tags": [ "NOMEN" ] }, { "uuid": "74744655-d1c4-4e2e-8c18-f82bafb95bd1", "citation": "Dopamine Receptor D2 (long isoform) (D2L)", "url": "https://www.discoverx.com/target-data-sheets/gpcr/drd2l", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "ac96fade-884d-4cae-954d-472d83182ec2", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8771b3ac-1f55-42f0-804d-fd1beaace74a", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ca7ad6ed-3c12-437d-9655-0a4b895b37b3", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8e2ffa0a-6d23-428d-bc2b-dd0f2e1f7394", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "47b80f5d-1d2d-4fcd-a28b-0cefe7c972f1", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "fb92cc75-2cf5-4dde-9ee0-d5c2255b823b", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "6eb22e02-3510-4b0b-b597-fa5d7c2d07c7", "citation": "https://en.wikipedia.org/wiki/Raclopride", "url": "https://en.wikipedia.org/wiki/Raclopride", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ea92d0f7-dd6f-45b8-ba07-02d96c056e5d", "citation": "https://jpet.aspetjournals.org/content/early/2021/07/12/jpet.121.000698", "url": "https://jpet.aspetjournals.org/content/early/2021/07/12/jpet.121.000698", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "62810686-2d13-449f-8447-0be1fde0d387", "citation": "Packeu, Ann, Jean‐Paul De Backer, and Georges Vauquelin. \"Non‐competitive interaction between raclopride and spiperone on human D2L‐receptors in intact Chinese hamster ovary cells.\" Fundamental & clinical pharmacology 24.3 (2010): 283-291.", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/j.1472-8206.2009.00793.x", "doc_type": "JA", "public_domain": true }, { "uuid": "58cf4f0a-3b54-4f5b-964c-6089edca0557", "citation": "https://go.drugbank.com/drugs/DB04888", "url": "https://go.drugbank.com/drugs/DB04888", "doc_type": "DRUG BANK", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "3344cf74-41fc-47b2-93e1-9baf7217bccd", "citation": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/sarizotan", "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/sarizotan", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c91c90ea-9d5e-4c7e-9dc8-6ebfe9b46924", "citation": "https://www.sciencedirect.com/topics/medicine-and-dentistry/sibenadet", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/sibenadet", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "85a44353-8e5b-47ba-a01c-26608e62eed3", "citation": "https://drugs.ncats.io/drug/N33SZ2N85M", "url": "https://drugs.ncats.io/drug/N33SZ2N85M", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "06aa3710-72a4-42b7-b5d9-3148809c1cd4", "citation": "Pan, Xiongfeng, et al. \"Dopamine and dopamine receptors in Alzheimer’s disease: a systematic review and network meta-analysis.\" Frontiers in aging neuroscience 11 (2019): 175.", "url": "https://www.frontiersin.org/articles/10.3389/fnagi.2019.00175/full", "doc_type": "JA", "public_domain": true }, { "uuid": "1594db8a-b50e-43b8-b683-c1beb4fe5dfc", "citation": "Pasini E, Cargnioni A, Pastore F, Razzetti R, Bongrani S, Gitti GL, Ferrari R. Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan;49(1):1-5. doi: 10.1016/s1043-6618(03)00246-9. PMID: 14597145.", "url": "https://pubmed.ncbi.nlm.nih.gov/14597145/", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "64a7d5cf-2338-4d37-88ef-37486e8d6f4d", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "bb342841-3bff-4916-8efc-bfb73456af1e", "citation": "Selent, Jana, et al. \"Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles.\" European Journal of Medicinal Chemistry 77 (2014): 91-95.t binding profiles", "url": "https://www.sciencedirect.com/science/article/pii/S0223523414001962#bib6", "doc_type": "JA", "public_domain": true }, { "uuid": "d883606d-9b5c-45c8-9743-cc9ab06a8d78", "citation": "https://www.drugbank.ca/drugs/DB00363", "doc_type": "WEBSITE", "public_domain": true }, { "uuid": "b63c9ce4-db84-49e2-99ab-51dbd94adfd8", "citation": "https://www.drugbank.ca/drugs/DB00363", "doc_type": "WEBSITE", "public_domain": true }, { "uuid": "7203fc44-f567-4fe7-b619-84317e9c6514", "citation": "Tadori, Yoshihiro, et al. \"Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.\" European journal of pharmacology 515.1-3 (2005): 10-19.", "url": "https://www.sciencedirect.com/science/article/pii/S0014299905004024", "doc_type": "JA", "public_domain": true }, { "uuid": "d11c066f-f936-4f01-9da5-ce43633be1c0", "citation": "Davies, Marilyn A., Douglas J. Sheffler, and Bryan L. Roth. \"Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.\" CNS drug reviews 10.4 (2004): 317-336.", "url": "file:///C:/Users/CALLAHANL/Downloads/1300203%20(1).pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "290607a6-3ddd-4659-9348-ecf1016670be", "citation": "Shapiro, David A., et al. \"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.\" Neuropsychopharmacology 28.8 (2003): 1400-1411.", "url": "https://www.nature.com/articles/1300203", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "1758577a-ae96-43b3-8331-fac299d97d96", "citation": "Cosi, Cristina, et al. \"Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist.\" European Journal of Pharmacology 890 (2021): 173635.", "url": "https://www.sciencedirect.com/science/article/pii/S0014299920307275", "doc_type": "JA", "public_domain": true }, { "uuid": "d7857d0b-4942-4914-a831-6cb4f402cd37", "citation": "https://www.drugbank.ca/drugs/DB01224", "doc_type": "WEBSITE", "public_domain": true }, { "uuid": "97b81331-f472-45e3-850d-5a0d21fae389", "citation": "https://www.ias.ac.in/article/fulltext/jbsc/045/0130", "url": "https://www.ias.ac.in/article/fulltext/jbsc/045/0130", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c47c2a2a-8f73-41f4-a2b0-563515c94b90", "citation": "https://go.drugbank.com/drugs/DB12061", "url": "https://go.drugbank.com/drugs/DB12061", "doc_type": "DRUG BANK", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "aefa277e-dead-4448-8c95-6a70a9b9a0c1", "citation": "https://drugs.ncats.io/drug/7SNB18Q89D", "url": "https://drugs.ncats.io/drug/7SNB18Q89D", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "95ddcac4-a971-4871-987b-f85b93b5ff0a", "citation": "https://www.dovepress.com/experimental-serotonergic-agents-for-the-treatment-of-schizophrenia-peer-reviewed-fulltext-article-JEP", "url": "https://www.dovepress.com/experimental-serotonergic-agents-for-the-treatment-of-schizophrenia-peer-reviewed-fulltext-article-JEP", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "77f1f4e1-7b11-460e-9da8-290d089e640a", "citation": "Osinski, Mark A., et al. \"Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets.\" Pharmacology Biochemistry and Behavior 81.1 (2005): 211-219.", "url": "https://www.sciencedirect.com/science/article/pii/S0091305705001139#bib26", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "dd64a69e-9da6-4dd5-aa71-bee86caf4363", "citation": "Lublin, Henrik, et al. \"Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.\" European Neuropsychopharmacology 1.4 (1991): 541-548.", "url": "https://www.sciencedirect.com/science/article/pii/0924977X9190008I", "doc_type": "JA", "public_domain": true }, { "uuid": "7b8c6695-2568-4c06-929b-b0759d081af1", "citation": "https://go.drugbank.com/drugs/DB08922", "url": "https://go.drugbank.com/drugs/DB08922", "doc_type": "DRUG BANK", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "47c3dd21-47b1-435e-b0e7-23644f62ab85", "citation": "WEBSITE", "url": "https://comptox.epa.gov/dashboard/dsstoxdb/results?utf8=%E2%9C%93&search=749-02-0", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "e279dc23-41e3-491b-9e68-509f6e29ef8f", "citation": "Palacios, J. M., D. L. Niehoff, and M. J. Kuhar. \"[3H] Spiperone binding sites in brain: autoradiographic localization of multiple receptors.\" Brain research 213.2 (1981): 277-289.", "url": "https://link.springer.com/content/pdf/10.1007/BF01250639.pdf", "doc_type": "JA", "public_domain": true }, { "uuid": "92318e2e-790f-4a40-8206-4e482e9ec683", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "18225ea2-5a92-478b-a0c5-529e8975cd7c", "citation": "Nichols, David E., et al. \"Lysergamides of isomeric 2, 4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD).\" Journal of Medicinal Chemistry 45.19 (2002): 4344-4349.", "url": "https://pubs.acs.org/doi/pdf/10.1021/jm020153s", "doc_type": "JA", "public_domain": true }, { "uuid": "8d2dac73-7c02-46ed-b871-aa00ad63564e", "citation": "https://drugs.ncats.io/drug/419A0R564U", "url": "https://drugs.ncats.io/drug/419A0R564U", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "bcfee1b3-a51d-48f2-a227-aceb76623ba3", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "3f5374cb-8bf1-44d8-bff6-226457434dea", "citation": "Nerkar, A., and S. Bhise. \"Polypharmacological Drugs in Treatment of Schizophrenia.\" Curr. Trends Pharm. Pharm. Chem 2.3 (2020): 116-124.", "url": "https://www.researchgate.net/profile/Amit-Nerkar/publication/343916662_Polypharmacological_Drugs_in_Treatment_of_Schizophrenia/links/5f47b64a299bf13c503efab3/Polypharmacological-Drugs-in-Treatment-of-Schizophrenia.pdf", "doc_type": "JA", "public_domain": true }, { "uuid": "df15fc23-8048-457a-b1f4-47c7f1fd245f", "citation": "https://www.sciencedirect.com/topics/chemistry/serotonin-5-ht2-receptor-antagonist", "url": "https://www.sciencedirect.com/topics/chemistry/serotonin-5-ht2-receptor-antagonist", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "1e05c04b-602e-4b33-a10a-1eabd75a9ae1", "citation": "https://go.drugbank.com/drugs/DB09223", "url": "https://go.drugbank.com/drugs/DB09223", "doc_type": "DRUG BANK", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "b3fd576a-107f-4f03-bfd2-f292981535da", "citation": "P122", "doc_type": "INN", "public_domain": true }, { "uuid": "74bfedca-6bae-4003-9f1c-4553e564c22e", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "e88c6a62-67f5-4029-8262-d91bede33bd4", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "3b6cb00e-6422-45ba-8b07-5d0ab8673bd2", "citation": "Bourne, James A. \"SCH 23390: the first selective dopamine D1‐like receptor antagonist.\" CNS drug reviews 7.4 (2001): 399-414.", "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2001.tb00207.x?sid=nlm%3Apubmed", "doc_type": "JA", "public_domain": true }, { "uuid": "889a61bc-9b6a-4c1e-82a8-ebe407c586aa", "citation": "Bourne, James A. \"SCH 23390: the first selective dopamine D1‐like receptor antagonist.\" CNS drug reviews 7.4 (2001): 399-414.", "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2001.tb00207.x?sid=nlm%3Apubmed", "doc_type": "JA", "public_domain": true }, { "uuid": "e1721362-1433-4aa9-827d-0b8493aeddeb", "citation": "https://www.drugbank.ca/drugs/DB01614", "doc_type": "WEBSITE", "public_domain": true }, { "uuid": "4c47c600-f9f2-49a3-b84c-2cdb9c6502fe", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/1322", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "3ff4aba9-7364-4fb2-af0b-82b2535aaf64", "citation": "https://www.sciencedirect.com/topics/chemistry/serotonin-5-ht2-receptor-antagonist", "url": "https://www.sciencedirect.com/topics/chemistry/serotonin-5-ht2-receptor-antagonist", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] } ], "definition_type": "PRIMARY", "definition_level": "COMPLETE", "uuid": "8a5e8a47-f550-4902-8d11-e0aa6920db0b", "version": "223", "unii": "19GBD6T9L7", "relationships": [ { "uuid": "6b0bcf5b-6151-49f4-b8cf-976da5811f64", "amount": { "uuid": "cc1b557d-138e-41d4-a22a-24e69695e0d5" }, "type": "PARTIAL AGONIST->TARGET", "references": [ "048a98f5-69a1-4f12-9974-9ba71391f812" ], "related_substance": { "uuid": "3abe19e9-b132-48a7-88c0-316981e8ff5d", "refuuid": "284493a4-5c93-4388-a176-f8a4a200d5e6", "name": "SALVINORIN A", "unii": "T56W91NG6J", "linking_id": "T56W91NG6J", "ref_pname": "SALVINORIN A" } }, { "uuid": "5cf65e43-b35c-4cea-b81c-a825551d7484", "amount": { "uuid": "f5b738af-7128-4927-9a53-3f93ca2de373" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "8afafad2-1f87-4ec5-89ef-b958a4456a94", "refuuid": "9e031f92-c418-4b2e-9d42-291ea6a39c1a", "name": "PIRIBEDIL", "unii": "DO22K1PRDJ", "linking_id": "DO22K1PRDJ", "ref_pname": "PIRIBEDIL" } }, { "uuid": "720d555e-1538-4de2-a5b5-886679fc2412", "amount": { "uuid": "4575c62c-a073-4658-9b3f-34992d424b47" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "c320d3c3-8461-4c52-8790-5ef55cda47a9", "refuuid": "74eb96da-1f5b-4bad-9687-8a221557fb5a", "name": "BROMOCRIPTINE", "unii": "3A64E3G5ZO", "linking_id": "3A64E3G5ZO", "ref_pname": "BROMOCRIPTINE" } }, { "uuid": "c64dfb7c-d391-4a86-a3bc-07a549cf35c7", "amount": { "uuid": "7ba34dda-3a15-4c7f-b114-1f32eefc3127" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "74b5c5bc-613d-42a4-be6e-69866d6788f4", "refuuid": "1cb18bf2-78d1-4d18-abbc-218d62b16b44", "name": "TALIPEXOLE", "unii": "7AM2J46Z1Y", "linking_id": "7AM2J46Z1Y", "ref_pname": "TALIPEXOLE" } }, { "uuid": "6251650e-03b7-494b-a654-16206a303689", "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "7437bbc8-4483-4513-a46c-92b97805b507", "refuuid": "42ffe2b2-b976-43fc-b5d5-c701cc060176", "name": "OSU-6162", "unii": "0D21EQAQQA", "linking_id": "0D21EQAQQA", "ref_pname": "OSU-6162" } }, { "uuid": "125881fc-2f60-436f-856c-14eabea0c0bb", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "1c2d52ce-1355-4502-bc7b-b90155a25a34", "refuuid": "81e28d47-0a99-4f45-9c10-6fabdba37779", "name": "ARMODAFINIL", "unii": "V63XWA605I", "linking_id": "V63XWA605I", "ref_pname": "ARMODAFINIL" } }, { "uuid": "0208f3ac-ec96-45fc-9ceb-171d863565dd", "type": "AGONIST->TARGET", "related_substance": { "uuid": "349e7ebb-846c-48aa-a467-acfc6eab6151", "refuuid": "4f896ce6-0ec7-4e72-bcda-78f8bb10cde4", "name": "SUMANIROLE", "unii": "3E93IV1U45", "linking_id": "3E93IV1U45", "ref_pname": "SUMANIROLE" } }, { "uuid": "cb2fa132-ca06-458f-ae98-5e0d411e17ef", "type": "AGONIST->TARGET", "related_substance": { "uuid": "68e8ceab-41e9-459d-84cb-616708d72334", "refuuid": "c7599a6a-1d8e-423c-91ed-00a93b353687", "name": "QUINPIROLE", "unii": "20OP60125T", "linking_id": "20OP60125T", "ref_pname": "QUINPIROLE" } }, { "uuid": "1a33e96d-c4c3-4f0d-8d2c-b8f4bc39486f", "type": "AGONIST->TARGET", "related_substance": { "uuid": "bed91f92-27ca-4d26-ae42-b2bc2aa3c543", "refuuid": "6872b294-ccf5-4307-b290-8e59d68478d2", "name": "CQA-206-291", "unii": "9I4I0M95U7", "linking_id": "9I4I0M95U7", "ref_pname": "CQA-206-291" } }, { "uuid": "ea62fe9f-d896-4166-af6a-1440aee9ab1b", "type": "AGONIST->TARGET", "related_substance": { "uuid": "ba3cab37-c137-4bc5-8783-88745b466017", "refuuid": "42309f06-bb6c-4965-90ab-debd7c516554", "name": "ROPINIROLE", "unii": "030PYR8953", "linking_id": "030PYR8953", "ref_pname": "ROPINIROLE" } }, { "uuid": "8441dfdd-175b-4a9b-87e7-0b443c760972", "amount": { "uuid": "a7e83b82-5d41-47b9-8b03-7f22fd252b19", "average": 1.3, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "c944595d-8190-48ad-9f12-816229dfa66d", "5718337b-370e-4692-84be-40889810b6d6" ], "related_substance": { "uuid": "47e45a06-144f-4fa8-a514-68dc0e46c44f", "refuuid": "808ccc92-143e-4add-8354-aee687e82627", "name": "ASENAPINE", "unii": "JKZ19V908O", "linking_id": "JKZ19V908O", "ref_pname": "ASENAPINE" } }, { "uuid": "594a6bb6-5788-4b60-b997-d3bdcdf1d8ed", "amount": { "uuid": "d4b9ecf9-71ac-4c97-a00d-4bd0f3512138", "average": 626, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "d7857d0b-4942-4914-a831-6cb4f402cd37" ], "related_substance": { "uuid": "a2ea120e-8210-48b7-bf4b-69e78d8d483d", "refuuid": "b98bca06-28a3-4da1-9914-6264bf3b8231", "name": "QUETIAPINE", "unii": "BGL0JSY5SI", "linking_id": "BGL0JSY5SI", "ref_pname": "QUETIAPINE" } }, { "uuid": "90994571-a404-4244-b4e7-3f0b47da98af", "amount": { "uuid": "215b8b13-e428-4532-ad2d-493c283d1d86" }, "type": "INHIBITOR->TARGET", "references": [ "e1721362-1433-4aa9-827d-0b8493aeddeb" ], "related_substance": { "uuid": "8488e3c8-29bd-4631-be41-7d3ee46cda16", "refuuid": "a6813f76-45ad-4c49-80e7-5a414d9a4691", "name": "ACEPROMAZINE", "unii": "54EJ303F0R", "linking_id": "54EJ303F0R", "ref_pname": "ACEPROMAZINE" } }, { "uuid": "796f6f1c-2c30-4b92-9c6c-b3580d896477", "amount": { "uuid": "3d7ced19-76fa-4c40-beae-0d4123dccfed", "average": 19, "units": "NANOMOLAR" }, "comments": "D2S Primary receptor interaction.. Emax 79%", "qualification": "EC50", "type": "AGONIST->TARGET", "references": [ "e424bfdb-fb12-40ce-b9ac-05c8be9ea918", "68c9cfda-b324-4fde-87a4-026cc9c059b8" ], "related_substance": { "uuid": "984ffd3c-7d6d-4ac4-86a8-61ca56e05dad", "refuuid": "d5382a9f-4b7e-432d-bf4d-03a5473c8f22", "name": "APOMORPHINE", "unii": "N21FAR7B4S", "linking_id": "N21FAR7B4S", "ref_pname": "APOMORPHINE" } }, { "uuid": "c3e1a627-6c69-4479-aae9-0121bfd12bb0", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "d857b6ca-d964-4da7-a1f1-a4d234edf906", "refuuid": "00c6d8ab-7895-4c2e-a470-8545033e9ca3", "name": "BUSPIRONE", "unii": "TK65WKS8HL", "linking_id": "TK65WKS8HL", "ref_pname": "BUSPIRONE" } }, { "uuid": "88a51d28-459d-4832-b69a-b7fc7666c93f", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "a2c3a048-37b3-48fe-99b7-16b67d3f68d6", "refuuid": "47bc90d6-b94c-4476-831e-36f446110b2a", "name": "SSR-181507", "unii": "H276H25KW0", "linking_id": "H276H25KW0", "ref_pname": "SSR-181507" } }, { "uuid": "581ceea3-db65-49df-8c1b-a555c5bce0e6", "type": "AGONIST->TARGET", "related_substance": { "uuid": "d802a98e-0c5f-43af-a362-cbdb7b082b9e", "refuuid": "a3cbd3a3-7846-4771-b0d0-7c6b4441cf8d", "name": "PERGOLIDE", "unii": "24MJ822NZ9", "linking_id": "24MJ822NZ9", "ref_pname": "PERGOLIDE" } }, { "uuid": "5aeb6f0c-595d-4646-9cff-0d4ab0505ee3", "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "f609c848-61af-4858-8932-c44b2e888700", "refuuid": "290d9815-8602-4636-ab28-7497ef98895b", "name": "Brilaroxazine", "unii": "X8L60BA01I", "linking_id": "X8L60BA01I", "ref_pname": "Brilaroxazine" } }, { "uuid": "e9b56093-9933-43a3-b1a5-0c63b28fc5f5", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "3ac76085-0a69-4cb1-987e-b70beb8fb309", "refuuid": "911506b4-23de-4357-a697-363249c77f93", "name": "ZIPRASIDONE", "unii": "6UKA5VEJ6X", "linking_id": "6UKA5VEJ6X", "ref_pname": "ZIPRASIDONE" } }, { "uuid": "ad95f841-9e74-4618-890a-719335ede862", "amount": { "uuid": "1479ff43-e1e4-44ed-81c3-5bb76d630d09", "average": 40, "units": "NANOMOLAR" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "e71fe757-34f3-40be-9e8d-27894b73782b", "refuuid": "6fca0332-91d4-44db-b125-81cc3c1639ea", "name": "SB-773812", "unii": "ZNP5SNF9FY", "linking_id": "ZNP5SNF9FY", "ref_pname": "SB-773812" } }, { "uuid": "a978e908-2e43-4517-b899-08f329a69f0d", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "0ebd199c-cc5f-475b-b46d-c18176d952c9", "refuuid": "447c2cba-218d-43cd-961d-6eab9df8dabd", "name": "TRIFLUOPERAZINE", "unii": "214IZI85K3", "linking_id": "214IZI85K3", "ref_pname": "TRIFLUOPERAZINE" } }, { "uuid": "f73425d6-aea5-4555-8f7e-5e4c0406d778", "type": "AGONIST->TARGET", "related_substance": { "uuid": "b5f99c69-8eed-423b-b99b-ee7195826c94", "refuuid": "23ecdee4-0740-40b6-b006-395ed0d40ac6", "name": "ROTIGOTINE", "unii": "87T4T8BO2E", "linking_id": "87T4T8BO2E", "ref_pname": "ROTIGOTINE" } }, { "uuid": "4c193e48-3665-45bd-bd52-404c1efd822c", "amount": { "uuid": "182ac31a-e398-443a-86a2-e6b7c2f6dbec", "average": 88.65, "high": 98.69, "low": 78.61, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "b63c9ce4-db84-49e2-99ab-51dbd94adfd8", "bb342841-3bff-4916-8efc-bfb73456af1e" ], "related_substance": { "uuid": "02bedc05-406c-45ff-91c3-82cb84fb0ec1", "refuuid": "002c8cd7-743e-4796-b590-7db2200653ff", "name": "CLOZAPINE", "unii": "J60AR2IKIC", "linking_id": "J60AR2IKIC", "ref_pname": "CLOZAPINE" } }, { "uuid": "40a6acb0-5f32-4b04-ba64-09d2442e26f2", "type": "LIGAND->TARGET", "related_substance": { "uuid": "2864a016-9ddc-47e3-b8df-c14fbf5ec0f2", "refuuid": "113fb06d-b1ce-4c49-bdad-7240e72c12ac", "name": "ISOREMOXIPRIDE", "unii": "GH32HX9WCX", "linking_id": "GH32HX9WCX", "ref_pname": "ISOREMOXIPRIDE" } }, { "uuid": "0efcaf43-e67c-4f2a-bd13-210c7eb6d230", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "ff244908-5ce7-4b85-aeae-74adbb6beba8", "refuuid": "6bdef611-e7fd-4605-a5a9-035cc8d113e9", "name": "PERPHENAZINE", "unii": "FTA7XXY4EZ", "linking_id": "FTA7XXY4EZ", "ref_pname": "PERPHENAZINE" } }, { "uuid": "c2740f8a-631f-4b3f-bf74-533f2ce47f82", "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "db83277f-4642-44ec-8c08-40e3e69c6c81", "refuuid": "11bc2623-db8f-4de6-b3e4-76dc8058607e", "name": "ROXINDOLE", "unii": "43227SMS0O", "linking_id": "43227SMS0O", "ref_pname": "ROXINDOLE" } }, { "uuid": "0df3b31a-c82b-496c-bc36-2d2598977063", "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "b601fc0f-6184-4c65-a933-9fbaed551b9b", "refuuid": "37cb7724-ac98-4895-8702-b82c3652926b", "name": "APLINDORE", "unii": "Q5O76TA0ML", "linking_id": "Q5O76TA0ML", "ref_pname": "APLINDORE" } }, { "uuid": "61092985-8557-48b4-ac8d-a23ceeea39a5", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "2ff1cea6-0ebd-4824-baa3-62b8ce46cf08", "refuuid": "bd271f99-3f4b-4ffa-88a6-bae0aa82d6e0", "name": "PROMAZINE", "unii": "O9M39HTM5W", "linking_id": "O9M39HTM5W", "ref_pname": "PROMAZINE" } }, { "uuid": "c91abb4e-39ac-4e1b-880e-3672e9d8bc3c", "amount": { "uuid": "a983eaee-d438-4f38-8fd9-77bac7e6b5fe", "average": 1.8, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "6eb22e02-3510-4b0b-b597-fa5d7c2d07c7" ], "related_substance": { "uuid": "e29e5ee3-78d4-4eb5-b095-c818947c14e6", "refuuid": "60bb5373-f75c-4688-bece-689e121085f0", "name": "RACLOPRIDE", "unii": "430K3SOZ7G", "linking_id": "430K3SOZ7G", "ref_pname": "RACLOPRIDE" } }, { "uuid": "7e0a3658-f20f-4a48-8008-7a3dfe6ddf6e", "amount": { "uuid": "0e5ae5b5-cfad-4c63-b597-52f7f26c36b9", "average": 0.49, "units": "NANOMOLAR" }, "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "aacc786d-935e-48e5-9d1f-4542e6a88b7b", "refuuid": "c2b826fe-75d5-4d80-b36a-3bec1d7c5e24", "name": "CARIPRAZINE", "unii": "F6RJL8B278", "linking_id": "F6RJL8B278", "ref_pname": "CARIPRAZINE" } }, { "uuid": "63c9b362-7677-4fab-9984-22f9e0339ba3", "type": "AGONIST->TARGET", "related_substance": { "uuid": "297a5e3e-a785-485f-9b68-e16e14ff287b", "refuuid": "597c8ee0-b354-4ac9-93f9-99a3ac360ff2", "name": "CABERGOLINE", "unii": "LL60K9J05T", "linking_id": "LL60K9J05T", "ref_pname": "CABERGOLINE" } }, { "uuid": "de509285-23f5-41fd-93d7-75f4c14c26ba", "type": "RADIOLIGAND->TARGET", "related_substance": { "uuid": "caa54fe5-09c8-49f1-a910-29e84b3d5b6a", "refuuid": "433b29bf-8969-4ee4-a503-02b5ec7341ee", "name": "FALLYPRIDE F-18", "unii": "ZF3G9J6G7I", "linking_id": "ZF3G9J6G7I", "ref_pname": "FALLYPRIDE F-18" } }, { "uuid": "4510c3f7-6bda-412c-8561-9edb0f54fff5", "type": "AGONIST->TARGET", "related_substance": { "uuid": "a3b5c198-71cf-49e3-ba26-242675a50c27", "refuuid": "9ee9b355-b747-4bfd-b7ab-527d509a784c", "name": "QUINELORANE", "unii": "Z0X4VT3Y1Q", "linking_id": "Z0X4VT3Y1Q", "ref_pname": "QUINELORANE" } }, { "uuid": "f6f3905a-f2e0-45bf-ab53-17501229b88e", "type": "AGONIST->TARGET", "related_substance": { "uuid": "e4536fcc-db07-4257-a10d-8251d94f2a42", "refuuid": "4dae9454-8311-4528-8b18-4d4a3f4e6d32", "name": "PRAMIPEXOLE", "unii": "83619PEU5T", "linking_id": "83619PEU5T", "ref_pname": "PRAMIPEXOLE" } }, { "uuid": "d6ea647e-fa5c-4b68-847b-10d345ed0ff9", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "a651ce89-150b-49c4-8aab-f5c3b5adb9b8", "refuuid": "a6bb7ead-77e0-462c-965b-02b04ef45260", "name": "SERTINDOLE", "unii": "GVV4Z879SP", "linking_id": "GVV4Z879SP", "ref_pname": "SERTINDOLE" } }, { "uuid": "e41b21e2-364a-40d9-93d9-f69e90a335f7", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "16068819-3b1a-4cf5-9768-fbe6b040e863", "refuuid": "7c7cefa1-9e09-4173-8307-526d79607b34", "name": "CHLORPROMAZINE", "unii": "U42B7VYA4P", "linking_id": "U42B7VYA4P", "ref_pname": "CHLORPROMAZINE" } }, { "uuid": "1f922fce-e43e-4ec5-85fd-0f935433b6ee", "type": "PARTIAL AGONIST->TARGET", "related_substance": { "uuid": "022c19d1-c700-48db-b854-aee04ea2e706", "refuuid": "fec3c362-3682-478a-a04b-0c667eddd7f7", "name": "BREXPIPRAZOLE", "unii": "2J3YBM1K8C", "linking_id": "2J3YBM1K8C", "ref_pname": "BREXPIPRAZOLE" } }, { "uuid": "08fcf70e-fd5c-4d7e-9da4-26dd10eb4923", "amount": { "uuid": "d55badb4-4f0c-4383-8670-38454a55446a", "high": 32, "low": 19.2, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "ANTAGONIST->TARGET", "interaction_type": "BINDING", "references": [ "8f98ee6c-257c-45f6-b3d8-be3b37d235fa" ], "related_substance": { "uuid": "1f24676c-5373-4452-9569-00627ff0b0a0", "refuuid": "7c562b37-d1d2-46e0-8737-abfa9a9a5aec", "name": "Lumateperone", "unii": "70BSQ12069", "linking_id": "70BSQ12069", "ref_pname": "Lumateperone" } }, { "uuid": "1cd0826f-ee04-4ea7-90e0-67b3b40eff31", "amount": { "uuid": "f11b7710-1e96-43df-936b-1fe2694da1aa" }, "type": "AGONIST->TARGET", "references": [ "702f6fa8-d005-458a-94e7-bacf1cfb7e49" ], "related_substance": { "uuid": "0ba2d8b6-c37b-4ef3-8d06-55c85f799402", "refuuid": "e1a71ff1-e062-4d2e-9963-3190666fdce4", "name": "ONZIGOLIDE", "unii": "L32IM11DV4", "linking_id": "L32IM11DV4", "ref_pname": "ONZIGOLIDE" } }, { "uuid": "765abe99-05c0-4109-8bdc-1f81a99f2856", "amount": { "uuid": "6feacbc6-f3f7-4ed8-964b-edbffb50fed8", "units": "NANOMOLAR", "high_limit": 6.3 }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "interaction_type": "MAJOR", "references": [ "5cdb941a-b124-4af6-8b9e-c651bc57b5a4" ], "related_substance": { "uuid": "2a2c1dbe-6dc8-48ec-9f08-8bbe3f517ac5", "refuuid": "f1476505-8361-4080-8a97-c6b9a0fb89ed", "name": "ILOPERIDONE", "unii": "VPO7KJ050N", "linking_id": "VPO7KJ050N", "ref_pname": "ILOPERIDONE" } }, { "uuid": "a974c143-9f65-4834-905e-0742c49e053f", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "bc7031cc-a4ad-40ae-974c-3ac5261f3cf8", "refuuid": "37fe7e40-fd61-4276-8bd4-0cc0ba8596c0", "name": "ONC-206", "unii": "OW6LM47PNK", "linking_id": "OW6LM47PNK", "ref_pname": "ONC-206" } }, { "uuid": "d5db80d8-4029-4067-888b-dcf470469675", "type": "ANTAGONIST->TARGET", "interaction_type": "SELECTIVE", "references": [ "712489ee-d8ee-40e5-8b57-6d4c842b19f5" ], "related_substance": { "uuid": "b22cb834-6da7-4b78-9c0f-697244cc26d0", "refuuid": "95bb2237-a7ee-4915-9473-84238cba0854", "name": "AMISULPRIDE", "unii": "8110R61I4U", "linking_id": "8110R61I4U", "ref_pname": "AMISULPRIDE" } }, { "uuid": "6e80c49e-0eb3-43a9-80a7-b573b2a0645a", "amount": { "uuid": "6b29fc6b-66cf-44ba-9e43-bcc83eff407f" }, "comments": "D2R concentration levels were significantly lower in AD patients than in healthy controls (SMD = −1.13, 95%CI: −1.52 to −0.74), with low heterogeneity (I2 = 7.80%), when USA studies were considered.", "type": "AGONIST->TARGET", "references": [ "06aa3710-72a4-42b7-b5d9-3148809c1cd4" ], "related_substance": { "uuid": "e2ead9f9-dc63-42bc-92e4-7c3f2cd34c9a", "refuuid": "11cfc6b9-4651-4a5c-98b9-284d8fbe2b50", "name": "DOPAMINE", "unii": "VTD58H1Z2X", "linking_id": "VTD58H1Z2X", "ref_pname": "DOPAMINE", "substance_class": "reference" } }, { "uuid": "ae73dc04-6f25-469e-9764-306d2bc3d9a6", "type": "INHIBITOR->TARGET", "references": [ "5de97546-2c14-4f0e-a53b-6683e713a815" ], "related_substance": { "uuid": "ddd1ed98-f93b-4a05-ba03-72d74797cf45", "refuuid": "0c4ec675-36a3-49ce-9bf5-47d9d9f9ec5e", "name": "ESAMISULPRIDE", "unii": "ES3TWM82E8", "linking_id": "ES3TWM82E8", "ref_pname": "ESAMISULPRIDE" } }, { "uuid": "e33a0366-fac9-47e3-8a80-c8be67094399", "type": "INHIBITOR->TARGET", "references": [ "77f40706-07bb-4631-8487-897b4cdecf5a" ], "related_substance": { "uuid": "ef9b586b-de52-4b6e-9eac-e57f7b41f263", "refuuid": "9f2aa717-4057-41e3-b056-8bc81935a644", "name": "METOPIMAZINE", "unii": "238S75V9AV", "linking_id": "238S75V9AV", "ref_pname": "METOPIMAZINE" } }, { "uuid": "95b11d61-e7b1-4882-a0fa-35d29c821d9d", "amount": { "uuid": "5d2ee830-0baf-4b29-ac36-04c25ccd3d2e" }, "type": "INHIBITOR->TARGET", "references": [ "b3fd576a-107f-4f03-bfd2-f292981535da" ], "related_substance": { "uuid": "63f631ae-261e-4155-a5f7-5ba0b524cf54", "refuuid": "f606f8e8-daca-4d36-b97f-d9c9a78f3e77", "name": "ARAMISULPRIDE", "unii": "B4J10KD2KI", "linking_id": "B4J10KD2KI", "ref_pname": "ARAMISULPRIDE" } }, { "uuid": "a94f7756-5353-4703-b077-6553901d0ab9", "type": "AGONIST->TARGET", "interaction_type": "PARTIAL AGONIST", "references": [ "520a3fd6-bbde-42f6-8eab-8ef207eb17cb" ], "related_substance": { "uuid": "69aa2c00-bbb1-4fdb-a2aa-7b8e5ae64c03", "refuuid": "6afb11d5-7bc9-4ec9-8969-9fdab4f484bd", "name": "CI-1007", "unii": "Z5XDS9Z25L", "linking_id": "Z5XDS9Z25L", "ref_pname": "CI-1007" } }, { "uuid": "4fc01b4a-b60b-4afa-9c26-18de53a35ed1", "amount": { "uuid": "deb38483-690d-48bb-95bf-7f36804ea61e", "average": 2.2, "high": 2.8, "low": 1.6, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "interaction_type": "INHIBITOR", "references": [ "99563024-e0ea-4f6b-bb5b-30745f4dbc87" ], "related_substance": { "uuid": "55773ad0-32e3-40aa-882d-dc6aa319ed2f", "refuuid": "d8f372eb-a89e-47ec-a957-bcdb1111df0b", "name": "PALIPERIDONE", "unii": "838F01T721", "linking_id": "838F01T721", "ref_pname": "PALIPERIDONE" } }, { "uuid": "921c78de-32e5-4962-98f9-14830dc754bc", "type": "AGONIST->TARGET", "references": [ "20c58ea2-ef23-487b-b4d9-eaac57742577" ], "related_substance": { "uuid": "1ce8c422-c763-4df6-84ae-e1f9808335c8", "refuuid": "94bfb98b-2425-417f-ac47-fb940f2c3eae", "name": "SUNEPITRON", "unii": "2GT50C8U60", "linking_id": "2GT50C8U60", "ref_pname": "SUNEPITRON" } }, { "uuid": "24bb8643-4168-440e-8023-d45baade8788", "amount": { "uuid": "22c6514b-ddd9-45cd-a3f2-d6c159e7fc77", "average": 3.2, "high": 4, "low": 2.4, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "interaction_type": "INHIBITOR", "references": [ "e811f88e-3b72-4077-90ac-2b2bd2adf43f" ], "related_substance": { "uuid": "f8ded80e-a335-4c99-a892-e386ffdce7e1", "refuuid": "95270949-f3d1-440d-8635-faa62495c858", "name": "RISPERIDONE", "unii": "L6UH7ZF8HC", "linking_id": "L6UH7ZF8HC", "ref_pname": "RISPERIDONE" } }, { "uuid": "a9525a5d-3668-470a-9690-7db843b7adf0", "type": "INHIBITOR->TARGET", "references": [ "560fe97a-3150-4a93-8110-f2c5dcc910e5" ], "related_substance": { "uuid": "f65b1c25-f31e-4416-984d-b9ad05b24d38", "refuuid": "669d1176-0ccd-44ce-a9ec-4f6ffd69916c", "name": "OCAPERIDONE", "unii": "26HUS7139V", "linking_id": "26HUS7139V", "ref_pname": "OCAPERIDONE" } }, { "uuid": "8b1f458a-7792-41f5-b47d-d294dd2c2719", "amount": { "uuid": "9529b713-13fe-4a71-87cd-4d424f49ed69" }, "type": "INHIBITOR->TARGET", "references": [ "cda44665-bfdb-4bd3-b556-7fb067960681" ], "related_substance": { "uuid": "d1bd49be-0eb8-4113-96b6-9ff150929293", "refuuid": "5a98174a-e869-4f53-aa37-79f5f6cfda7e", "name": "MAFOPRAZINE", "unii": "D7UUO54C6N", "linking_id": "D7UUO54C6N", "ref_pname": "MAFOPRAZINE", "substance_class": "reference" } }, { "uuid": "6df6f8c6-4607-49c9-9fc2-8260f835a451", "amount": { "uuid": "e4c0889f-1c3b-451a-9423-b1c97a3f1b28" }, "type": "INHIBITOR->TARGET", "references": [ "8d23b4ac-48ff-472b-83bc-d0cffb719db2" ], "related_substance": { "uuid": "8e95b374-3921-4300-a706-e92a50abe93b", "refuuid": "4d1d43bb-50ff-4b5b-871e-d3799ef83747", "name": "THIOTHIXENE", "unii": "7318FJ13YJ", "linking_id": "7318FJ13YJ", "ref_pname": "THIOTHIXENE" } }, { "uuid": "371c3490-488a-4853-8f9a-55a19bae23ec", "amount": { "uuid": "9b429a3e-781e-421a-9cf8-4700fdf021b6" }, "type": "AGONIST->TARGET", "references": [ "47b80f5d-1d2d-4fcd-a28b-0cefe7c972f1" ], "related_substance": { "uuid": "8448b4e5-dc72-49ef-9ead-96ab227ac640", "refuuid": "f51c196c-6cf2-4e95-a3ea-435b44b0bd57", "name": "6-FLUORO-DMT", "unii": "J4CZH8D9EN", "linking_id": "J4CZH8D9EN", "ref_pname": "6-FLUORO-DMT" } }, { "uuid": "2e86655a-b536-4dd8-92d7-bcff6aa7874e", "amount": { "uuid": "0a68fb88-b579-4de2-9513-c1fdc199715b", "average": 3.9, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "RADIOLIGAND->TARGET", "related_substance": { "uuid": "d7a6abbf-7d68-438a-a57b-bf97b9e92d06", "refuuid": "b821fd25-ff3c-449c-bc12-e697a10efd71", "name": "MBL C-11", "unii": "R1KWM2Z2QN", "linking_id": "R1KWM2Z2QN", "ref_pname": "MBL C-11", "substance_class": "reference" } }, { "uuid": "fb40957d-936b-4d1f-8098-ca171ce757be", "amount": { "uuid": "89b0a855-4c26-4fa4-b3a4-0c6709287bf3" }, "type": "INHIBITOR->TARGET", "references": [ "97b81331-f472-45e3-850d-5a0d21fae389" ], "related_substance": { "uuid": "c385f8d5-f559-4357-9a66-aacded931506", "refuuid": "890445e0-4cb4-4616-9d13-01c1ea1992a3", "name": "LENSIPRAZINE", "unii": "N47MW76OGX", "linking_id": "N47MW76OGX", "ref_pname": "LENSIPRAZINE", "substance_class": "reference" } }, { "uuid": "423fde98-c531-4393-afcc-aecd3fe4c6d9", "amount": { "uuid": "d8a8cd53-1dc0-485c-bf0f-55e7c3dd2874" }, "type": "INHIBITOR->TARGET", "references": [ "5929a3e2-5efd-4b69-a4cd-d02328ba965f" ], "related_substance": { "uuid": "791c3500-8288-4898-95ca-f074698511c7", "refuuid": "46b1d623-7fed-4849-85c8-887ee0949e23", "name": "ORDOPIDINE", "unii": "0P43SIA7J6", "linking_id": "0P43SIA7J6", "ref_pname": "ORDOPIDINE", "substance_class": "reference" } }, { "uuid": "b01f4d00-206d-411a-8f97-2b61872025fc", "amount": { "uuid": "4052a8a0-e6ec-4f81-b76c-a9f890a08cad" }, "type": "INHIBITOR->TARGET", "references": [ "3d2995a8-6ba9-4be6-b206-83462fd138d5" ], "related_substance": { "uuid": "36c0c7e6-3fd9-4b31-ad30-479e3e492318", "refuuid": "377155c3-f95a-450d-8190-cf1ca83fbf30", "name": "R-167154", "unii": "Y48NWN4BHC", "linking_id": "Y48NWN4BHC", "ref_pname": "R-167154", "substance_class": "reference" } }, { "uuid": "8216bd24-5824-4b20-9138-06f74d93d5cb", "amount": { "uuid": "8deb9e4e-593e-4d24-aa20-73ac6aef390b", "average": 2.9, "units": "NANOMOLAR" }, "comments": "Binding Assay", "qualification": "IC50", "type": "INHIBITOR->TARGET", "references": [ "653f9470-fd4f-4331-92bb-da840f932a81" ], "related_substance": { "uuid": "895dcbd5-ab7d-45a3-9a72-d610f9cadf82", "refuuid": "ee082c4f-fdea-4b52-9e9a-c849914f49dc", "name": "BUTACLAMOL", "unii": "A7A2802VNL", "linking_id": "A7A2802VNL", "ref_pname": "BUTACLAMOL", "substance_class": "reference" } }, { "uuid": "00eb0bd1-0ef5-4eeb-aa23-49d7cba203cf", "amount": { "uuid": "a2ee1d92-1772-4558-9447-1a2bb6b40ea7" }, "type": "RADIOLIGAND->TARGET", "references": [ "38ba70f9-5336-4c97-9841-c833e6a9e1fa" ], "related_substance": { "uuid": "8f110ea0-8afd-469e-a670-54ae9940c0ca", "refuuid": "dd9fade1-f070-45e6-9dbb-86aa2e122a0d", "name": "SPIPERONE H-3", "unii": "8KZ649LMN4", "linking_id": "8KZ649LMN4", "ref_pname": "SPIPERONE H-3" } }, { "uuid": "b3e4928a-6e25-4195-9acd-f101dc4b9819", "amount": { "uuid": "d8d54330-36d2-4ea0-b227-61444506693a" }, "type": "AGONIST->TARGET", "references": [ "ca7ad6ed-3c12-437d-9655-0a4b895b37b3" ], "related_substance": { "uuid": "57fd9bf6-200a-4621-926d-dd5c4e10da82", "refuuid": "b714e0ee-d080-4552-924e-a8a46a576f43", "name": "DINOXYLINE", "unii": "9T7B8CV47A", "linking_id": "9T7B8CV47A", "ref_pname": "DINOXYLINE" } }, { "uuid": "6e0181ed-0455-4052-a503-47654b5c6090", "amount": { "uuid": "8ee33ea3-bc33-4046-a669-94b9437158e4" }, "type": "LIGAND->TARGET", "references": [ "64a7d5cf-2338-4d37-88ef-37486e8d6f4d" ], "related_substance": { "uuid": "4e13a916-a5ca-4a9c-8f2c-9f91666d42cf", "refuuid": "ac43e7aa-ec0e-42ab-9e8d-3c05e6725be0", "name": "1-(3-Chlorophenyl)-4-(2-phenylethyl)piperazine", "unii": "3LEH2E7AEU", "linking_id": "3LEH2E7AEU", "ref_pname": "1-(3-Chlorophenyl)-4-(2-phenylethyl)piperazine" } }, { "uuid": "3530dfbf-dd26-4817-a25c-405ac8645993", "amount": { "uuid": "fe345347-6cf4-409a-a49a-f963249e9fff" }, "type": "INHIBITOR->TARGET", "references": [ "95cbea44-2697-423d-91c1-95c526cbdbf0" ], "related_substance": { "uuid": "fcb77103-860d-4d35-8701-fda2426497a4", "refuuid": "e72458ca-0a2f-4b74-a9db-be86d8ffd5ae", "name": "NARONAPRIDE", "unii": "058896B00B", "linking_id": "058896B00B", "ref_pname": "NARONAPRIDE", "substance_class": "reference" } }, { "uuid": "71c4a859-5dd7-4562-ba89-bf97721a7629", "amount": { "uuid": "4824da80-2010-48e4-b591-5b6dfdc71c54" }, "type": "INHIBITOR->TARGET", "references": [ "4421af0d-a03b-4391-8a6e-0b4ec1e9fe9f" ], "related_substance": { "uuid": "4c0caee2-9c6a-4496-a679-d921d1f0c276", "refuuid": "853e38c8-ffda-4379-bfb6-e8bf16b17b6a", "name": "PIMOZIDE", "unii": "1HIZ4DL86F", "linking_id": "1HIZ4DL86F", "ref_pname": "PIMOZIDE", "substance_class": "reference" } }, { "uuid": "fd8be932-3480-4bb1-8c13-b6b0fc95f625", "amount": { "uuid": "6d6abfc6-a539-487e-a585-651a0c24983a" }, "type": "INHIBITOR->TARGET", "references": [ "8e2ffa0a-6d23-428d-bc2b-dd0f2e1f7394" ], "related_substance": { "uuid": "bfaf955f-c5be-4312-8758-3480b3cdc12d", "refuuid": "fc36a808-b655-4f51-ac3e-9975ac32350f", "name": "6-(2-(4-(BENZO(D)ISOTHIAZOL-3-YL)PIPERAZIN-1-YL)ETHYL)-4,4,8-TRIMETHYL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE", "unii": "XL77275YFN", "linking_id": "XL77275YFN", "ref_pname": "6-(2-(4-(BENZO(D)ISOTHIAZOL-3-YL)PIPERAZIN-1-YL)ETHYL)-4,4,8-TRIMETHYL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE", "substance_class": "reference" } }, { "uuid": "55a95ac7-032c-4dc6-8231-b936703bd1cb", "amount": { "uuid": "135e3bfc-b692-4a4a-9cee-5588fa7d8080", "average": 0.329, "units": "NANOMOLAR" }, "comments": "cell:CHO K1; ligand:3H-spiperone", "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "58d5b633-d571-428d-91e1-35ba05cc644b" ], "related_substance": { "uuid": "69f49e7e-5abc-487d-8455-f6af3ab2ad30", "refuuid": "2396a3bb-89b5-4463-8698-8393d7cfeb94", "name": "Lurasidone", "unii": "22IC88528T", "linking_id": "22IC88528T", "ref_pname": "Lurasidone" } }, { "uuid": "e8982faa-c3bb-40f6-b49d-c21106483c6d", "amount": { "uuid": "f1d82cef-8f75-4bab-a948-68f0d9223b1f" }, "type": "LIGAND->TARGET", "references": [ "fb92cc75-2cf5-4dde-9ee0-d5c2255b823b" ], "related_substance": { "uuid": "a2c105de-2d24-479e-8005-856a47d74778", "refuuid": "8cfbe220-5321-436d-8c54-cc19d68ca0c6", "name": "CYANODOTHIEPIN", "unii": "KK5VES2GLD", "linking_id": "KK5VES2GLD", "ref_pname": "CYANODOTHIEPIN" } }, { "uuid": "db5d403c-f8ff-411f-8e66-b6736ffe72d1", "amount": { "uuid": "51c4088a-6225-4476-821b-e06564e742fb", "average": 0.3, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INVERSE AGONIST->TARGET", "interaction_type": "BINDING", "related_substance": { "uuid": "2fca2a3f-b6ba-4ae2-be1f-1e818d4546e3", "refuuid": "cb034a38-8a43-4112-9760-cae598710d66", "name": "HALOPERIDOL", "unii": "J6292F8L3D", "linking_id": "J6292F8L3D", "ref_pname": "HALOPERIDOL", "substance_class": "reference" } }, { "uuid": "dcdc8975-4524-483e-8852-9aad59ef600e", "amount": { "uuid": "d56af779-bb2d-460b-9724-de90c75ceda0" }, "type": "INHIBITOR->TARGET", "references": [ "ea92d0f7-dd6f-45b8-ba07-02d96c056e5d" ], "related_substance": { "uuid": "719472d4-79ac-458a-bea2-1e6763142642", "refuuid": "59346899-cf62-4a03-8574-a706654ef917", "name": "TRAZPIROBEN", "unii": "FH87H57Q4Y", "linking_id": "FH87H57Q4Y", "ref_pname": "TRAZPIROBEN", "substance_class": "reference" } }, { "uuid": "f37d9276-cf08-4386-8ea2-d9874cca918c", "amount": { "uuid": "f7dfb490-4691-404d-8a60-b1085db7484a", "average": 1.3, "units": "NANOMOLAR" }, "qualification": "IC50", "type": "INHIBITOR->TARGET", "interaction_type": "BINDING", "references": [ "47c3dd21-47b1-435e-b0e7-23644f62ab85", "e279dc23-41e3-491b-9e68-509f6e29ef8f", "92318e2e-790f-4a40-8206-4e482e9ec683" ], "related_substance": { "uuid": "fdad4df5-8f04-4463-894d-d0cc6c17cb6a", "refuuid": "fdd73a64-5e81-4e14-8b3e-b3064d4099da", "name": "SPIPERONE", "unii": "4X6E73CJ0Q", "linking_id": "4X6E73CJ0Q", "ref_pname": "SPIPERONE" } }, { "uuid": "31df342f-a584-4257-a91e-90a69edc742b", "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "d72181ea-2e46-4f2e-8197-cf4279ff6ca4" ], "related_substance": { "uuid": "ff06089a-9895-482e-86b9-59e048dea44e", "refuuid": "6da14dc0-0741-4dee-bf23-259b32b38404", "name": "DESMETHOXYFALLYPRIDE", "unii": "CJD4EF9EME", "linking_id": "CJD4EF9EME", "ref_pname": "DESMETHOXYFALLYPRIDE" } }, { "uuid": "937a9438-c7e0-45c4-8992-3ff4737fe606", "amount": { "uuid": "415bf4e7-f5c6-4b2e-80e2-b392d5f106e1" }, "type": "INHIBITOR->TARGET", "references": [ "df15fc23-8048-457a-b1f4-47c7f1fd245f" ], "related_substance": { "uuid": "12c199d8-a58c-4c11-a264-de3988a4a7d3", "refuuid": "fb3ed3fc-c13d-4658-a5b7-fda923dc48be", "name": "GEVOTROLINE", "unii": "7SZ6A2091Q", "linking_id": "7SZ6A2091Q", "ref_pname": "GEVOTROLINE", "substance_class": "reference" } }, { "uuid": "f17f84ad-89ad-4289-a381-3f344a464034", "amount": { "uuid": "4950a355-3cce-4e1d-a770-a293221d4f23" }, "type": "INHIBITOR->TARGET", "references": [ "3ff4aba9-7364-4fb2-af0b-82b2535aaf64" ], "related_substance": { "uuid": "20a77829-bf4d-4fed-82a8-8929fcc82441", "refuuid": "0d76c5d2-af51-4862-a5f7-87ed3df8bff1", "name": "CARVOTROLINE", "unii": "1Q63WWP8G5", "linking_id": "1Q63WWP8G5", "ref_pname": "CARVOTROLINE", "substance_class": "reference" } }, { "uuid": "468bed71-3580-4ad5-8804-ab5b5f277516", "amount": { "uuid": "f6beffc2-a063-4a58-a33e-8d3458a911f3" }, "type": "INHIBITOR->TARGET", "references": [ "8d2dac73-7c02-46ed-b871-aa00ad63564e" ], "related_substance": { "uuid": "97cd6c62-4557-41fe-8993-0c0939a6672b", "refuuid": "458f966c-d4da-4fdb-b056-bcb4d135a15e", "name": "ELOPIPRAZOLE", "unii": "419A0R564U", "linking_id": "419A0R564U", "ref_pname": "ELOPIPRAZOLE", "substance_class": "reference" } }, { "uuid": "207dc169-a278-4e20-8cf7-73a0644f1bec", "amount": { "uuid": "c39e56da-585e-4cf7-a218-87082dcf6352" }, "type": "AGONIST->TARGET", "references": [ "77f1f4e1-7b11-460e-9da8-290d089e640a" ], "related_substance": { "uuid": "0e4699ed-c5ff-481d-ab73-b77e188cca02", "refuuid": "43c937a3-df68-4d08-975f-1ed9bee31374", "name": "PNU-142774E", "unii": "KJN6KTF7D8", "linking_id": "KJN6KTF7D8", "ref_pname": "PNU-142774E", "substance_class": "reference" } }, { "uuid": "aef5de1f-c259-4877-9bb7-f2f3b5372c2a", "amount": { "uuid": "62b3105e-e253-4e10-bd27-125cb7e58d29", "high": 6, "low": 1.9, "units": "NANOMOLAR" }, "comments": " Co-incubation with a D2L-dopamine receptor sub-saturating concentration of raclopride produced an apparent decrease in the equilibrium dissociation constant of the radioligand (i.e. KD = 6.0 nm vs. 1.9 nm ", "qualification": "Kd", "type": "RADIOLIGAND->TARGET", "interaction_type": "NON-COMPETITIVE", "references": [ "62810686-2d13-449f-8447-0be1fde0d387" ], "related_substance": { "uuid": "a6d4a998-7b6e-4afc-a871-cdcc7e1e0e83", "refuuid": "e733696c-502d-4aaf-a780-14a8c72ba8b6", "name": "RACLOPRIDE C-11", "unii": "GE077RPG04", "linking_id": "GE077RPG04", "ref_pname": "RACLOPRIDE C-11", "substance_class": "reference" } }, { "uuid": "838b9e4f-5f18-4b80-b26c-cd2b7727aeb9", "amount": { "uuid": "ec4ff0c0-22c7-4231-a512-46feaf13681f", "average": 0.68, "units": "NANOMOLAR" }, "qualification": "Kd", "type": "RADIOLIGAND->TARGET", "references": [ "74bfedca-6bae-4003-9f1c-4553e564c22e" ], "related_substance": { "uuid": "4588d585-06dd-461b-8cec-3037d86db39f", "refuuid": "d2699699-0001-4378-9802-91b2ceb352f2", "name": "7-OH-DPAT H-3", "unii": "BE5P7MQG2K", "linking_id": "BE5P7MQG2K", "ref_pname": "7-OH-DPAT H-3", "substance_class": "reference" } }, { "uuid": "5e1325e2-b8d0-4020-ad83-3a2de856cd9f", "amount": { "uuid": "edbecc45-3793-42d5-ad24-59f18038eec4", "average": 2.3, "units": "NANOMOLAR" }, "qualification": "IC50", "type": "INHIBITOR->TARGET", "interaction_type": "BINDING", "references": [ "e88c6a62-67f5-4029-8262-d91bede33bd4" ], "related_substance": { "uuid": "ee668507-b704-4345-b9f2-ef4694010025", "refuuid": "1ea50b92-5707-41a1-a2c9-05b5453692a5", "name": "7-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN", "unii": "RR7D75YDF4", "linking_id": "RR7D75YDF4", "ref_pname": "7-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN", "substance_class": "reference" } }, { "uuid": "4210ff37-2a8f-4708-9dee-838a3228e2a6", "amount": { "uuid": "83530b26-7b79-4859-8a15-1d9180757116" }, "type": "INHIBITOR->TARGET", "references": [ "7b8c6695-2568-4c06-929b-b0759d081af1" ], "related_substance": { "uuid": "70704e0c-4243-414c-87eb-6ccb5fdbcca7", "refuuid": "15abd28f-f148-4c2e-b57e-cedec17f04ba", "name": "PEROSPIRONE", "unii": "N303OK87DT", "linking_id": "N303OK87DT", "ref_pname": "PEROSPIRONE", "substance_class": "reference" } }, { "uuid": "1aabe3e9-1bb4-43f3-b480-0f531a0bdaa8", "amount": { "uuid": "c07e5a34-829c-415c-9822-39ed284cc161", "average": 2.1, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "3f5374cb-8bf1-44d8-bff6-226457434dea" ], "related_substance": { "uuid": "bb395b3c-ff72-462e-ae20-b7db131aa189", "refuuid": "44113624-19ec-4631-951f-e3a91606efb8", "name": "BROMPERIDOL", "unii": "LYH6F7I22E", "linking_id": "LYH6F7I22E", "ref_pname": "BROMPERIDOL", "substance_class": "reference" } }, { "uuid": "e93d5a27-3dca-46c2-80aa-bbac90d050b6", "amount": { "uuid": "5b34d268-69f2-4ff4-acaf-be44e008949a", "average": 120, "high": 157, "low": 83, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "LIGAND->OFF TARGET", "interaction_type": "BINDING", "references": [ "18225ea2-5a92-478b-a0c5-529e8975cd7c" ], "related_substance": { "uuid": "a4095637-99fb-4381-a9a7-aad76ccfcf0f", "refuuid": "47838978-2214-4228-a38b-9ed5b1b283a3", "name": "LYSERGIDE", "unii": "8NA5SWF92O", "linking_id": "8NA5SWF92O", "ref_pname": "LYSERGIDE", "substance_class": "reference" } }, { "uuid": "78bd5774-e350-4032-8076-58d12066042e", "amount": { "uuid": "8752c8f5-15b5-419d-b1e7-302fac07d684" }, "type": "AGONIST->TARGET", "references": [ "85a44353-8e5b-47ba-a01c-26608e62eed3" ], "related_substance": { "uuid": "91436861-3daf-4c0d-a4cd-eb725c917a78", "refuuid": "fb0aa412-b1d1-4f0c-b965-652dcc254545", "name": "LIREXAPRIDE", "unii": "N33SZ2N85M", "linking_id": "N33SZ2N85M", "ref_pname": "LIREXAPRIDE", "substance_class": "reference" } }, { "uuid": "be6303f7-01c6-4786-ac90-925ac28b9beb", "amount": { "uuid": "bd7c5868-d614-4dbb-9c16-4a136f712bdb" }, "type": "INHIBITOR->TARGET", "references": [ "1e05c04b-602e-4b33-a10a-1eabd75a9ae1" ], "related_substance": { "uuid": "db69716f-4229-41a9-a67c-9c7f6792ba17", "refuuid": "d0fa9211-2b23-4b76-be8f-760f995aaf7f", "name": "BLONANSERIN", "unii": "AQ316B4F8C", "linking_id": "AQ316B4F8C", "ref_pname": "BLONANSERIN", "substance_class": "reference" } }, { "uuid": "1f8c840c-ba27-4cf2-b45a-53de6beed0ab", "amount": { "uuid": "21109417-0b12-4cde-bda1-9a838573b000", "average": 12, "high": 12.3, "low": 11.7, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "1758577a-ae96-43b3-8331-fac299d97d96" ], "related_substance": { "uuid": "d73335d5-f200-4466-bb1a-0e8629b1174d", "refuuid": "c8be447d-d74f-4ac5-9f25-a45736d8c5cc", "name": "F-17464 FREE BASE", "unii": "TDB64DDB5X", "linking_id": "TDB64DDB5X", "ref_pname": "F-17464 FREE BASE", "substance_class": "reference" } }, { "uuid": "095934dd-7410-414e-889d-62fa8f81c2e0", "amount": { "uuid": "c75dfc8d-2e05-464b-a95d-5f6880ada4c1" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "e44729c2-ffbe-47b4-a80d-abea366c2e39", "refuuid": "98d31249-6ef8-427a-a709-ab35729bdb10", "name": "ABAPERIDONE", "unii": "40755Z8956", "linking_id": "40755Z8956", "ref_pname": "ABAPERIDONE", "substance_class": "reference" } }, { "uuid": "f1d1d561-b93e-4aab-9102-b6e0462de5ef", "amount": { "uuid": "f27057cb-abe1-4f4d-896f-c54d71dfeb3e" }, "type": "AGONIST->TARGET", "references": [ "1594db8a-b50e-43b8-b683-c1beb4fe5dfc" ], "related_substance": { "uuid": "f546342b-cf26-44c7-99df-077077bddbc8", "refuuid": "437e57d2-4d8b-43a4-9634-af5f00920dab", "name": "NOLOMIROLE", "unii": "6EMF80C55F", "linking_id": "6EMF80C55F", "ref_pname": "NOLOMIROLE", "substance_class": "reference" } }, { "uuid": "be75684b-6a15-4d65-84da-698443a47a97", "amount": { "uuid": "2bd4d03e-d791-408d-bfda-ec7c062db0ee" }, "type": "INHIBITOR->TARGET", "references": [ "3344cf74-41fc-47b2-93e1-9baf7217bccd" ], "related_substance": { "uuid": "7bbd6d5e-8c3b-4dae-a6f1-c2a721051c1a", "refuuid": "0641c6f4-b64b-4d12-b7c0-ce271bd158ed", "name": "SARIZOTAN", "unii": "467LU0UCUW", "linking_id": "467LU0UCUW", "ref_pname": "SARIZOTAN", "substance_class": "reference" } }, { "uuid": "ea1d956e-4dc9-460a-a114-cee3a04b904b", "amount": { "uuid": "3c73e783-da29-4cbc-b784-0ccda4e3b6bb" }, "type": "AGONIST->TARGET", "references": [ "c91c90ea-9d5e-4c7e-9dc8-6ebfe9b46924" ], "related_substance": { "uuid": "3a1b8928-94b0-418c-8084-7d08a0e79368", "refuuid": "1717f5a6-def3-45f5-a1f2-641c389069fc", "name": "SIBENADET", "unii": "N32934RHGW", "linking_id": "N32934RHGW", "ref_pname": "SIBENADET", "substance_class": "reference" } }, { "uuid": "509ec563-deea-4c8a-acd5-8e8fbb0d61a7", "amount": { "uuid": "c8496a69-294a-4a92-ae3c-2eefa6230aed" }, "type": "PARTIAL AGONIST->TARGET", "references": [ "58cf4f0a-3b54-4f5b-964c-6089edca0557" ], "related_substance": { "uuid": "33936324-14c2-498f-a2d0-678c8401f070", "refuuid": "2ca77445-a9fa-40dc-84d5-afd7e109e2bb", "name": "BIFEPRUNOX", "unii": "AP69E83Z79", "linking_id": "AP69E83Z79", "ref_pname": "BIFEPRUNOX", "substance_class": "reference" } }, { "uuid": "5b17beb9-4a8b-4cf2-bd86-46c8e9685d2d", "amount": { "uuid": "ab485104-0216-41fb-ac19-e8be301d8a41", "average": 0.74, "high": 0.83, "low": 0.65, "units": "NANOMOLAR" }, "comments": "Primary target for antipsychotic activity. The partial agonist actions of aripiprazole vary widely depending upon the cellular milieu. Thus, nearly fullagonism, weak partial agonism and frank antagonism, have all been reported, depending upon the assay system and cellular background. ", "qualification": "Ki", "type": "PARTIAL AGONIST->TARGET", "references": [ "d11c066f-f936-4f01-9da5-ce43633be1c0", "290607a6-3ddd-4659-9348-ecf1016670be" ], "related_substance": { "uuid": "3b32a427-bf31-44fc-8a30-d7fae2e2cb8f", "refuuid": "c193f733-fa48-4704-bbca-957a3c6dff6c", "name": "ARIPIPRAZOLE", "unii": "82VFR53I78", "linking_id": "82VFR53I78", "ref_pname": "ARIPIPRAZOLE", "substance_class": "reference" } }, { "uuid": "b2596340-f9f8-4151-9ec0-6ec1aa72ab5d", "amount": { "uuid": "e5cac835-f447-4912-84b7-87080f1db376", "high": 0.56, "low": 0.86, "units": "NANOMOLAR", "low_limit": 1.16 }, "qualification": "Ki", "type": "PARTIAL AGONIST->TARGET", "references": [ "7203fc44-f567-4fe7-b619-84317e9c6514" ], "related_substance": { "uuid": "4d446e3e-8544-4eb3-8a85-8d753eee3b1d", "refuuid": "b3551857-6e92-47b9-bd63-cf8d8ca2084c", "name": "TERGURIDE", "unii": "21OJT43Q88", "linking_id": "21OJT43Q88", "ref_pname": "TERGURIDE", "substance_class": "reference" } }, { "uuid": "2c44fd1e-fb91-45df-a06f-6442bc28c435", "amount": { "uuid": "913441b0-3b56-4cd0-a264-4ee5f83b9703" }, "type": "INHIBITOR->TARGET", "references": [ "95ddcac4-a971-4871-987b-f85b93b5ff0a" ], "related_substance": { "uuid": "a8a80e48-1103-45ca-a215-4390c0e7b045", "refuuid": "7406b90a-e42f-49b7-8aaa-be5043ade6de", "name": "ZICRONAPINE", "unii": "QZV11V7G6A", "linking_id": "QZV11V7G6A", "ref_pname": "ZICRONAPINE", "substance_class": "reference" } }, { "uuid": "dec36fcb-c1e8-478b-a02b-8332bc1e35e8", "amount": { "uuid": "dd913b0a-22e6-4fe5-9f89-43a2d1cb8e62", "average": 2.6, "units": "NANOMOLAR" }, "qualification": "IC50", "type": "INHIBITOR->TARGET", "interaction_type": "BINDING", "references": [ "4c47c600-f9f2-49a3-b84c-2cdb9c6502fe" ], "related_substance": { "uuid": "1c98cdff-0082-4c77-891d-011bab3770d9", "refuuid": "cb034a38-8a43-4112-9760-cae598710d66", "name": "HALOPERIDOL", "unii": "J6292F8L3D", "linking_id": "J6292F8L3D", "ref_pname": "HALOPERIDOL", "substance_class": "reference" } }, { "uuid": "32c09bc7-bef5-4a24-ab4d-9cc9e9034fd7", "amount": { "uuid": "8cae46e3-a077-4a02-82de-b8d2e41e2295" }, "type": "INHIBITOR->TARGET", "references": [ "aefa277e-dead-4448-8c95-6a70a9b9a0c1" ], "related_substance": { "uuid": "eea5bc89-4176-443f-b21e-77afd1a417eb", "refuuid": "df9ef20c-25d3-4a09-b6f2-c25302bebb60", "name": "ADOPRAZINE", "unii": "7SNB18Q89D", "linking_id": "7SNB18Q89D", "ref_pname": "ADOPRAZINE", "substance_class": "reference" } }, { "uuid": "a52606ee-8d76-4769-a143-b4842436150a", "amount": { "uuid": "77a17058-94c4-4806-962b-ff8b48fe8e6d" }, "type": "RADIOLIGAND->TARGET", "related_substance": { "uuid": "9fe025ac-2d83-4943-8bcf-b490e347bc96", "refuuid": "37736895-d413-4eed-8cea-956919705d3f", "name": "IOLOPRIDE I-123", "unii": "5E76SOQ99K", "linking_id": "5E76SOQ99K", "ref_pname": "IOLOPRIDE I-123", "substance_class": "reference" } }, { "uuid": "ef66ca92-756d-4577-a252-3f949e456bd2", "amount": { "uuid": "ffbed5b7-5d99-48e7-9dc2-83dd7bbdf100" }, "type": "PARTIAL AGONIST->TARGET", "references": [ "c47c2a2a-8f73-41f4-a2b0-563515c94b90" ], "related_substance": { "uuid": "3ccd2be4-1514-4392-b214-ade669d7c1ce", "refuuid": "fca1e40b-2e85-4ae2-957a-0c470db06eba", "name": "PARDOPRUNOX", "unii": "5R72CHP32S", "linking_id": "5R72CHP32S", "ref_pname": "PARDOPRUNOX", "substance_class": "reference" } }, { "uuid": "19403e87-56ab-4907-a64f-be871c0afdff", "amount": { "uuid": "f69e78fc-de36-4cd3-ab31-cc00f6aaf799" }, "type": "INHIBITOR->TARGET", "references": [ "dd64a69e-9da6-4dd5-aa71-bee86caf4363" ], "related_substance": { "uuid": "e2847c92-b66a-4bb7-84fb-d3aa0f56af2c", "refuuid": "b60c7573-3da3-435f-b90d-57f04b4c9a01", "name": "ZUCLOPENTHIXOL", "unii": "47ISU063SG", "linking_id": "47ISU063SG", "ref_pname": "ZUCLOPENTHIXOL", "substance_class": "reference" } }, { "uuid": "57e406a3-41fe-4be4-896b-096685332e21", "amount": { "uuid": "d3ebd10a-8a5e-4e09-be2a-efb6e33c7179", "average": 1.1, "units": "MICROMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->OFF-TARGET", "interaction_type": "BINDING", "references": [ "3b6cb00e-6422-45ba-8b07-5d0ab8673bd2" ], "related_substance": { "uuid": "50392ffc-70c0-4835-87f3-0e29cef4c31c", "refuuid": "13369292-c650-4ac4-be6a-dadb9d87a173", "name": "SCH-23390", "unii": "UGT5535REQ", "linking_id": "UGT5535REQ", "ref_pname": "SCH-23390", "substance_class": "reference" } }, { "uuid": "b44708bc-b2c2-4d29-95ac-79da0ab05f9a", "amount": { "uuid": "13e61606-faa8-4390-a5aa-4b0da2e4d250", "average": 1.2, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "889a61bc-9b6a-4c1e-82a8-ebe407c586aa" ], "related_substance": { "uuid": "3e5c59e3-7964-4188-883d-a0fba73c4523", "refuuid": "cb034a38-8a43-4112-9760-cae598710d66", "name": "HALOPERIDOL", "unii": "J6292F8L3D", "linking_id": "J6292F8L3D", "ref_pname": "HALOPERIDOL", "substance_class": "reference" } } ], "names": [ { "uuid": "a764c508-08ed-4aa0-ba8b-ad2046caf0af", "name": "D(2) DOPAMINE RECEPTOR", "stdName": "D(2) DOPAMINE RECEPTOR", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "7fdc675a-9238-494a-8877-6cfa08878db2", "fa5ad85a-51a9-4a93-ac80-9966529aa0c3" ], "display_name": true }, { "uuid": "3e8c59e5-4de2-47cb-b3a4-a54acdda2f2b", "name": "D2", "stdName": "D2", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "3741bcc3-f436-403d-80a0-3b34b77149e3" ], "display_name": false }, { "uuid": "d3c01ff4-6378-456e-852a-c0403f2839bd", "name": "D2(LONG)", "stdName": "D2(LONG)", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "fa5ad85a-51a9-4a93-ac80-9966529aa0c3", "7fdc675a-9238-494a-8877-6cfa08878db2" ], "display_name": false }, { "uuid": "9cc8c739-3927-ff13-1632-31e14d163890", "name": "D2R", "stdName": "D2R", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "f9aa99c5-50db-11c8-f648-9d4f71589099" ], "display_name": false }, { "uuid": "f75a8d85-b248-44ee-9f4f-eab3b158251c", "name": "DOPAMINE D2 RECEPTOR", "stdName": "DOPAMINE D2 RECEPTOR", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "fa5ad85a-51a9-4a93-ac80-9966529aa0c3", "3741bcc3-f436-403d-80a0-3b34b77149e3" ], "display_name": false }, { "uuid": "69255e97-23bc-4d07-b9b0-c73ccfbca03f", "name": "DRD2", "stdName": "DRD2", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "7fdc675a-9238-494a-8877-6cfa08878db2", "fa5ad85a-51a9-4a93-ac80-9966529aa0c3" ], "display_name": false }, { "uuid": "9f9434c7-c881-4a2b-bf2e-33792b7c111f", "name": "DRD2L", "stdName": "DRD2L", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "74744655-d1c4-4e2e-8c18-f82bafb95bd1" ], "display_name": false } ], "protein": { "uuid": "2b092ff0-b409-481c-8e91-d201d2955581", "glycosylation": { "uuid": "c752f86c-635f-43ff-88e0-82ec3ee8c6d5", "glycosylation_type": "HUMAN", "n_glycosylation_sites": [ { "residue_index": 5, "subunit_index": 1 }, { "residue_index": 17, "subunit_index": 1 }, { "residue_index": 23, "subunit_index": 1 } ] }, "subunits": [ { "uuid": "541beac3-20c8-4b3b-a8bb-eb25321a8812", "sequence": "MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVFGNVLVCMAVSREKALQTTTNYLIVSLAVADLLVATLVMPWVVYLEVVGEWKFSRIHCDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNNADQNECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTKRSSRAFRAHLRAPLKGNCTHPEDMKLCTVIMKSNGSFPVNRRRVEAARRAQELEMEMLSSTSPPERTRYSPIPPSHHQLTLPDPSHHGLHSTPDSPAKPEKNGHAKDHPKIAKIFEIQTMPNGKTRTSLKTMSRRKLSQQKEKKATQMLAIVLGVFIICWLPFFITHILNIHCDCNIPPVLYSAFTWLGYVNSAVNPIIYTTFNIEFRKAFLKILHC", "subunit_index": 1 } ], "references": [ "7fdc675a-9238-494a-8877-6cfa08878db2", "1c1864cd-bd16-4fdd-8961-6823e07db9d5" ], "disulfide_links": [ { "sites": [ { "residue_index": 107, "subunit_index": 1 }, { "residue_index": 182, "subunit_index": 1 } ] }, { "sites": [ { "residue_index": 399, "subunit_index": 1 }, { "residue_index": 401, "subunit_index": 1 } ] } ], "protein_sub_type": "", "sequence_origin": "HUMAN", "sequence_type": "COMPLETE" }, "properties": [ { "uuid": "8f041c30-bca9-467e-af97-cc702e3f29a7", "name": "MOL_WEIGHT", "type": "amount", "value": { "uuid": "f51d3619-09ba-4bd2-80cf-109d48ec8b70", "units": "DA" }, "defining": false, "property_type": "CHEMICAL" }, { "uuid": "2f5006ff-4e0a-4799-86d8-5da9372c1462", "name": "Molecular Formula", "value": { "uuid": "e962b90c-9534-4ee5-a379-ce065aa7a82f", "type": "ESTIMATED", "non_numeric_value": "C2293H3619O623N613S27" }, "defining": false, "property_type": "CHEMICAL" } ], "modifications": { "uuid": "f0bc4c21-df6b-4ff7-abe4-bc6f084187f5" } } ] }